Humana Stock Gets a Boost From Unexpected Decline in Medical Costs
Humana Stock Gets a Boost From Unexpected Decline in Medical Costs Barron's
Covered in this story
Analyst targets on Humana
- Baird: $432 → $596 by Oct 2027 · Outperform via Investing.com
- Barclays: $398 → $515 by Sep 2027 · Overweight via 247wallst.com
- Wolfe Research: $387 → $450 by Aug 2027 · Outperform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $HUM yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Humana →Summary aggregated from Barron's's public RSS feed. The full reporting belongs to Barron's — please read it on their site.